In teenagers with childhood-onset chronic pain unrelated to chronic disease, poor sleep quality and depression were risk factors for substance use in young adulthood.

Researchers explain how a device delivering mild electrical stimulation to the brain can safely and effectively treat depression symptoms.

Alto Neuroscience (Alto) has reported that its Phase IIb clinical trial of ALTO-100 for treating major depressive disorder ...

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...

Alto Neuroscience (ANRO) “announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its ...

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel ...

This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in ...

Supernus Pharmaceuticals has said its candidate SPN-820, demonstrated a “rapid and substantial” effect in a Phase IIa trial ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

Clinically meaningful improvement of –16.6 at four hours and –22.9 at Day 10 on the Montgomery Åsberg Depression Rating Scale (MADRS) total score ... enrollment in the Phase 2b randomized double-blind ...

Developed by neurologist John Kurtzke to replace his Disability Status Scale (DSS), it is a way of measuring disability and progression in multiple sclerosis. The EDSS is also used widely in clinical ...

Depression affects at least 350 million people around the world. Women are twice as likely to deal with its symptoms as men. Countless factors can influence how the female body and mind respond to ...